RxDoctor Payments Data

Victor Chavez

Pulmonary Disease · Evansville, INNPI 1700830593

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $41,500 of the $51,856 with a category attached, or 80.0%. GSK accounts for 81.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $23,184 and has fallen 62.1% since, to $8,787 in 2022. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,856in general payments, 2019–2025

Across 96 payments — averaging $540.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$42K
  • Intuitive Surgical$5K
  • Viiv Healthcare Company$4K
  • AstraZeneca$132
  • Pulmonx Corporation$102
  • Johnson & Johnson$75
  • plus $307 from 13 others

What the payments were for

  • Speaking & faculty fees$41,50080%
  • Travel & lodging$5,07910%
  • Food & beverage$2,1574%
  • Education$3,1206%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,856 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Other pulmonary disease in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →